Publication Date
1-18-2024
Journal
NPJ Breast Cancer
Abstract
In a 3-arm presurgical trial, four-six weeks exemestane 25 mg three times/week (TIW) was non-inferior to 25 mg/day (QD) in suppressing circulating estradiol in postmenopausal women with ER-positive breast cancer. Since obesity may decrease exemestane efficacy, we analyzed changes in sex steroids, adipokines, Ki-67, and drug levels in relation to obesity. Postmenopausal women with early-stage ER-positive breast cancer were randomized to either exemestane 25 mg QD (n = 57), 25 mg TIW (n = 57), or 25 mg/week (QW, n = 62) for 4-6 weeks before breast surgery. Serum and tissue pre- and post-treatment biomarkers were stratified by body mass index (BMI)< or ≥30 kg/m
Keywords
Cancer prevention, Randomized controlled trials
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Community Health and Preventive Medicine Commons, Medical Sciences Commons, Obstetrics and Gynecology Commons, Oncology Commons
Comments
Supplementary Materials
PMID: 38238336